Abstract:Gene therapy is the most promising treatment for recessive dystrophic epidermolysis bullosa (RDEB), however genetic cargo delivery efficiency is still a technical limitation. Viruses are the traditional vector of preference for gene therapy, as virus trophism increase tissue specificity. However, drawbacks related with safety and high manufacturing costs have facilitated the expansion of non-viral vectors, such as liposomes and cationic polymers. Our group is focused on the development of highly branched cationic polymers for gene therapy to treat RDEB. Our polymers have demonstrated encapsulation and delivery of a full COL7A1 cDNA with no toxicity, performing better transfection efficiencies than commercial counterparts in RDEB keratinocytes. In this work, we show the research progress expanding the polymer technology for mRNA and ribonucleoprotein complex delivery for developing CRISPR/Cas9 based gene editing therapies for RDEB. Gene edition in vivo has been achieved by a single topical application, obtaining efficiencies comparable with viral vectors (Ad5). Endosomal escape, by peptide polymer decoration is being investigated to improve efficiency in vivo by avoiding endosomal retention. Storage of the nanoparticles, formed by polymers and the genetic cargo, at -20C ensures no reduction in efficiency for more than 6 months. However, in order to avoid cold chain challenges, nanoparticles have been lyophilised, increasing dose concentration and facilitating formulation with skin absorption enhancers for topical application. Proven ability to transfect stem cells combined with high efficiencies transfecting with multiple plasmids at the same time, should contribute to the success of prime editing strategies to pursue permanent correction of potential >89% of all described EB disease-associated mutations. The developed polymer platform shows high potential to be adapted to a wide range of genetic approaches for RDEB, including the most novel ones.

532 Sirna Based Non-Viral Gene Therapy for the Treatment of Epidermolysis Bullosa Simplex(ebs)

476 Non-viral Gene Delivery Platform for Topically Treating Rare Genodermatoses

222 Formulation of a Novel High Performance Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

836 Non-viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Using a Highly Branched Poly(β-Amino Ester) Polymer (HPAE-EB)

834 CRISPR/Cas9 Based COL7A1 Genomic Editing in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Via Non-Viral Polymer Delivery System

CRISPR-Cas9-based Non-Viral Gene Editing Therapy for Topical Treatment of Recessive Dystrophic Epidermolysis Bullosa

Highly Branched Poly(β-Amino Ester)s for Gene Delivery in Hereditary Skin Diseases

A Knot Polymer Mediated Non-Viral Gene Transfection for Skin Cells

Efficient and Robust Highly Branched Poly(β-amino Ester)/minicircle COL7A1 Polymeric Nanoparticles for Gene Delivery to Recessive Dystrophic Epidermolysis Bullosa Keratinocytes

Non-viral Delivery of CRISPR–Cas9 Complexes for Targeted Gene Editing Via a Polymer Delivery System

455 Non-viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa: Hyper Branched Aminated Polyesters Mediated Minicircle DNA Delivery

An elastic liposomal formulation for RNAi-based topical treatment of skin disorders: Proof-of-concept in the treatment of psoriasis

Allele-specific CRISPR-Cas9 editing of dominant epidermolysis bullosa simplex in human epidermal stem cells

A Non‐viral Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa

398 A Simple, Efficient Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Development of Minicircle Vectors Encoding COL7A1 Gene with Human Promoters for Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa.

Beyond Branching: Multiknot Structured Polymer for Gene Delivery

Emerging DNA & RNA editing strategies for the treatment of epidermolysis bullosa

Highly Branched Poly(β-Amino Ester)s for Skin Gene Therapy.

An RNA-targeted therapy for dystrophic epidermolysis bullosa

200 A Comparison of Minicircle Vectors Expressing COL7A1 under the Control of Human Promoters for the Treatment of Recessive Dystrophic Epidermolysis Bullosa